| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 19 securities · passive | ||||||
|
Sutro Biopharma, Inc.
13G
STRO · 869367201
|
5.1% |
11/9/2026
Event 11/5/2026
|
||||
| Coastlands Capital LP | 5.1% | |||||
| Coastlands Capital Partners LP | 5.1% | |||||
| Coastlands Capital GP LLC | 5.1% | |||||
| Coastlands Capital LLC | 5.1% | |||||
| Matthew D. Perry | 5.1% | |||||
|
Bolt Biotherapeutics, Inc.
13G
BOLT · 097702203
|
17.5% |
11/6/2026
Event 10/30/2026
|
||||
| Coastlands Capital LP | 17.5% | |||||
| Coastlands Capital Partners LP | 17.5% | |||||
| Coastlands Capital GP LLC | 17.5% | |||||
| Coastlands Capital LLC | 17.5% | |||||
| Matthew D. Perry | 17.5% | |||||
|
Azora Therapeutics, Inc.
13G/A
054800107
|
4.99% |
11/3/2026
Event 11/2/2026
|
||||
| Coastlands Capital LP | 4.99% | |||||
| Coastlands Capital Partners LP | 4.99% | |||||
| Coastlands Capital GP LLC | 4.99% | |||||
| Coastlands Capital LLC | 4.99% | |||||
| Matthew D. Perry | 4.99% | |||||
|
Azora Therapeutics, Inc.
13G/A
054800107
|
4.99% |
11/2/2026
Event 11/2/2026
|
||||
| Coastlands Capital LP | 4.99% | |||||
| Coastlands Capital Partners LP | 4.99% | |||||
| Coastlands Capital GP LLC | 4.99% | |||||
| Coastlands Capital LLC | 4.99% | |||||
| Matthew D. Perry | 4.99% | |||||
|
Kalaris Therapeutics, Inc.
13G
KLRS · 482929106
|
5.7% |
10/26/2026
Event 10/19/2026
|
||||
| Coastlands Capital LP | 5.7% | |||||
| Coastlands Capital Partners LP | 5.7% | |||||
| Coastlands Capital GP LLC | 5.7% | |||||
| Coastlands Capital LLC | 5.7% | |||||
| Matthew D. Perry | 5.7% | |||||
|
Frazier Life Sciences Acquisition Corp. II
13G
G37103101
|
6.4% |
10/16/2026
Event 10/15/2026
|
||||
| Coastlands Capital LP | 6.4% | |||||
| Coastlands Capital Partners LP | 6.4% | |||||
| Coastlands Capital GP LLC | 6.4% | |||||
| Coastlands Capital LLC | 6.4% | |||||
| Matthew D. Perry | 6.4% | |||||
|
iBio, Inc.
13G
IBIO · 451033708
|
9.7% |
10/14/2026
Event 10/7/2026
|
||||
| Coastlands Capital LP | 9.7% | |||||
| Coastlands Capital Partners LP | 9.7% | |||||
| Coastlands Capital GP LLC | 9.7% | |||||
| Coastlands Capital LLC | 9.7% | |||||
| Matthew D. Perry | 9.7% | |||||
|
OnKure Therapeutics, Inc.
13G
OKUR · 68277Q105
|
6.7% |
10/7/2026
Event 10/1/2026
|
||||
| Coastlands Capital LP | 6.7% | |||||
| Coastlands Capital Partners LP | 6.7% | |||||
| Coastlands Capital GP LLC | 6.7% | |||||
| Coastlands Capital LLC | 6.7% | |||||
| Matthew D. Perry | 6.7% | |||||
|
Pyxis Oncology, Inc.
13G
PYXS · 747324101
|
5.4% |
10/5/2026
Event 10/1/2026
|
||||
| Coastlands Capital LP | 5.4% | |||||
| Coastlands Capital Partners LP | 5.4% | |||||
| Coastlands Capital GP LLC | 5.4% | |||||
| Coastlands Capital LLC | 5.4% | |||||
| Matthew D. Perry | 5.4% | |||||
|
Neuphoria Therapeutics Inc.
13G/A
NEUP · 64136E102
|
4.2% |
7/28/2026
Event 7/23/2026
|
||||
| Coastlands Capital LP | 4.2% | |||||
| Coastlands Capital Partners LP | 4.2% | |||||
| Coastlands Capital GP LLC | 4.2% | |||||
| Coastlands Capital LLC | 4.2% | |||||
| Matthew D. Perry | 4.2% | |||||
|
Adial Pharmaceuticals, Inc.
13G/A
ADIL · 00688A304
|
14.2% |
7/1/2026
Event 6/24/2026
|
||||
| Coastlands Capital LP | 14.2% | |||||
| Coastlands Capital Partners LP | 14.2% | |||||
| Coastlands Capital GP LLC | 14.2% | |||||
| Coastlands Capital LLC | 14.2% | |||||
| Matthew D. Perry | 14.2% | |||||
|
Pasithea Therapeutics Corp.
13G/A
KTTA · 70261F202
|
11.5% |
7/1/2026
Event 4/9/2026
|
||||
| Coastlands Capital LP | 11.5% | |||||
| Coastlands Capital Partners LP | 11.5% | |||||
| Coastlands Capital GP LLC | 11.5% | |||||
| Coastlands Capital LLC | 11.5% | |||||
| Matthew D. Perry | 11.5% | |||||
|
Eloxx Pharmaceuticals, Inc.
13G
ELOX · 29014R103
|
10.0% |
6/17/2026
Event 6/10/2026
|
||||
| Coastlands Capital LP | 10.0% | |||||
| Coastlands Capital Partners LP | 10.0% | |||||
| Coastlands Capital GP LLC | 10.0% | |||||
| Coastlands Capital LLC | 10.0% | |||||
| Matthew D. Perry | 10.0% | |||||
|
Minerva Neurosciences, Inc.
13G
NERV · 603380205
|
10.0% |
2/20/2026
Event 2/13/2026
|
||||
| Coastlands Capital LP | 10.0% | |||||
| Coastlands Capital Partners LP | 10.0% | |||||
| Coastlands Capital GP LLC | 10.0% | |||||
| Coastlands Capital LLC | 10.0% | |||||
| Matthew D. Perry | 10.0% | |||||
|
Eledon Pharmaceuticals, Inc.
13G/A
ELDN · 28617K101
|
4.99% |
2/13/2026
Event 12/31/2025
|
||||
| Coastlands Capital LP | 4.99% | |||||
| Coastlands Capital Partners LP | 4.99% | |||||
| Coastlands Capital GP LLC | 4.99% | |||||
| Coastlands Capital LLC | 4.99% | |||||
| Matthew D. Perry | 4.99% | |||||
|
Xilio Therapeutics, Inc.
13G
XLO · 98422T100
|
10.0% |
12/11/2025
Event 12/4/2025
|
||||
| Coastlands Capital LP | 10.0% | |||||
| Coastlands Capital Partners LP | 10.0% | |||||
| Coastlands Capital GP LLC | 10.0% | |||||
| Coastlands Capital LLC | 10.0% | |||||
| Matthew D. Perry | 10.0% | |||||
|
Camp4 Therapeutics Corp
13G/A
CAMP · 13463J101
|
10.0% |
12/11/2025
Event 9/10/2025
|
||||
| Coastlands Capital LP | 10.0% | |||||
| Coastlands Capital Partners LP | 10.0% | |||||
| Coastlands Capital GP LLC | 10.0% | |||||
| Coastlands Capital LLC | 10.0% | |||||
| Matthew D. Perry | 10.0% | |||||
|
X4 Pharmaceuticals, Inc.
13G
XFOR · 98420X202
|
10.0% |
10/3/2025
Event 10/3/2025
|
||||
| Coastlands Capital LP | 10.0% | |||||
| Coastlands Capital Partners LP | 10.0% | |||||
| Coastlands Capital GP LLC | 10.0% | |||||
| Coastlands Capital LLC | 10.0% | |||||
| Matthew D. Perry | 10.0% | |||||
|
Whitehawk Therapeutics, Inc.
13G
WHWK · 00032Q104
|
6.0% |
8/25/2025
Event 8/19/2025
|
||||
| Coastlands Capital LP | 6.0% | |||||
| Coastlands Capital Partners LP | 6.0% | |||||
| Coastlands Capital GP LLC | 6.0% | |||||
| Coastlands Capital LLC | 6.0% | |||||
| Matthew D. Perry | 6.0% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.